3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Breast Neoplasms
1
Interventions
Paclitaxel
71
Bevacizumab
64
Carboplatin
56
pembrolizumab
46
olaparib
32
Gemcitabine
29
Specimen Handling
27
Cyclophosphamide
26
liposomal doxorubicin
24
Magnetic Resonance Spectroscopy
24
Cisplatin
22
niraparib
21
Taxes
19
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
13
Disulfides
13
Fulvestrant
12
Blood Specimen Collection
11
durvalumab
10
Oxaliplatin
10
mirvetuximab soravtansine
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Histamine Antagonists
×
1 year
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled